Amgen Inc.
AMGN · NASDAQ-GS
Analyst Consensus
Hold
Analyst Ratings Synthesis
The supplied consensus is Hold across 24 analysts, with a mean price target of $425. Low and high targets are unavailable, so the target range and where individual targets cluster cannot be established; the mean is below the supplied latest close of $460.73. The evidence names neither the most bullish nor the least bullish analyst and provides no firm-level rating or target revisions for the past week, so the direction of revisions and the substantive analyst disagreement behind the target spread cannot be verified. The available debate is about whether drug-sales growth and clinical progress can outweigh biosimilar competition, pricing pressure and higher costs, rather than a documented change in analyst recommendations.
- Stocks Fall Sharply on Intel and Amazon Sell-offs and Crypto Heist
- AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth
- Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
- Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Daily Dividend Report: WFC,CTAS,WMB,ETN,BKR,AMGN
Rating Actions
No individual rating actions have been captured for AMGN yet. Consensus figures above come from Nasdaq's aggregate feed.
Research Reports
- Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
- Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?
- Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
- Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
- Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
- Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
- Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?
